

UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/027,205	02/20/1998	CARL H. JUNE	GIN-005	2825	
75	590 05/14/2002				
	JPERKO ESQ	EXAMI	EXAMINER		
HALE AND DO		ROARK, JESSICA H			
BOSTON, MA		ART UNIT	PAPER NUMBER		
			ARTUNII	PAPER NUMBER	
			1644	29	
		DATE MAILED: 05/14/2002	DATE MAILED: 05/14/2002		

Please find below and/or attached an Office communication concerning this application or proceeding.

Advisory Action

Application No.	Applicant(s)	-1, 500
09/027,205	JUNE ET AL.	
Examiner	 Art Unit	
Jessica H. Roark	1644	

		Jessica II. Roark	1044	<u> </u>			
	The MAILING DATE of this communication appe	ars on the cover sheet with the	e correspondence add	iress			
Theref final re conditi	EPLY FILED FAILS TO PLACE THIS APPROFE, further action by the applicant is required to a spection under 37 CFR 1.113 may only be either: (1) on for allowance; (2) a timely filed Notice of Appearation (RCE) in compliance with 37 CFR 1.114.	oid abandonment of this appl a timely filed amendment wh	ication. A proper replication. A proper replication is a polication of the community and the community	ation in			
	PERIOD FOR RE	PLY [check either a) or b)]					
a) [·	•					
b) L	The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire I ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS 706.07(f).	ater than SIX MONTHS from the ma	ling date of the final reject	ion.			
fee have fee unde (2) as se	ensions of time may be obtained under 37 CFR 1.136(a). The been filed is the date for purposes of determining the period of a 37 CFR 1.17(a) is calculated from: (1) the expiration date of the total form in (b) above, if checked. Any reply received by the Office ed, may reduce any earned patent term adjustment. See 37 CFR 1.136(a).	of extension and the corresponding a the shortened statutory period for re- ce later than three months after the n	mount of the fee. The app oly originally set in the final	ropriate extension Office action; or			
	A Notice of Appeal was filed on <u>09 April 2002</u> . Appe 37 CFR 1.192(a), or any extension thereof (37 CFF			n in			
2.	The proposed amendment(s) will not be entered be	ecause:					
(a)	they raise new issues that would require further	er consideration and/or search	(see NOTE below);				
(b)	☐ they raise the issue of new matter (see Note b	pelow);					
(c)	they are not deemed to place the application in issues for appeal; and/or	n better form for appeal by ma	terially reducing or si	mplifying the			
(d)	they present additional claims without cancel	ng a corresponding number o	f finally rejected claim	ns.			
	NOTE:	•					
3.□ /	Applicant's reply has overcome the following reject	ion(s):					
4.	Newly proposed or amended claim(s) would canceling the non-allowable claim(s).	be allowable if submitted in a	separate, timely filed	amendment			
5.🖾							
6.⊠	The affidavit or exhibit will NOT be considered bec raised by the Examiner in the final rejection.	ause it is not directed SOLEL	Y to issues which wer	e newly			
7.🛛	For purposes of Appeal, the proposed amendment explanation of how the new or amended claims we			and an			
•	The status of the claim(s) is (or will be) as follows:		MIP GAMBOL				
	Claim(s) allowed:		P GAMBEL, PH.D ARY EXAMINER				
	Claim(s) objected to:	-	neu connoc (600)				
	Claim(s) rejected: <u>1, 55, 60, 75 and 87-94</u> .		5/14/04				
	Claim(s) withdrawn from consideration:						
8.	The proposed drawing correction filed on is	a) ☐ approved or b) ☐ disa	pproved by the Exam	iner.			
9.	Note the attached Information Disclosure Statemen	nt(s)(PTO-1449) Paper No(s)					
10. Other:							





Continuation of 5.

does NOT place the application in condition for allowance because:

1. The Dr. C. June Declaration under 37 CFR 1.132 filed 4/29/02 is insufficient to overcome the rejection of claims 1, 55 87-90, 92 and 94 under 35 USC 102(a) and claims 1, 55, 60, 75, 87-89, 92 and 94 under 35 USC 103(a) based upon Levine et al. (Science 272:1939-1942 1996, IDS #CH) as set forth in the previous Office Actions (Paper Nos. 16, 19 and 26). The June Declaration has not been found sufficient for several reasons.

Paragraph 2 of the Declaration indicates that Dr. June is the Inventor of the subject matter that appears to be that recited in the instant claims; therefore, the Declaration raises issues under 35 USC 102(f) as to who invented the subject matter now claimed since the instant inventorship further includes Richard C. Carroll, James L. Riley and Daniel C. St. Louis.

In addition, in view of the statement in paragraph 2 of the Declaration that Dr. June invented the subject matter that appears to be that recited in the instant claims, the statement in paragraph 4 does not address the contribution of all authors of the Levine et al. reference. Therefore, the reference is still "by others".

It is also noted that the Declaration provides only conclusory statements as to the role of the other authors of the Levine et al. reference without setting forth the basis for this opinion, such as what the role of the other co-authors were and why these roles do not contribute to conception of the instant invention. Neither does the Declaration provide a clear indication that the other authors were merely working under his direction, as per MPEP 715.01(c).

Finally, the Declaration was not timely filed in response to the rejections of record originally set forth in Paper No. 16.

For these reasons, the Declaration of Dr. C. June under 37 CFR 1.132 is not found to be sufficient to overcome the rejections of record with respect to Levine et al.

2. In addition, claims 1, 55, 60, 75, 87-89, 92 and 94 stand rejected under 35 USC 102(e) as anticipated by Chang (U.S. Pat. No. 6,129,916), and claims 1, 55, 60, 75, 91 and 93 stand rejected under 35 USC 103(a) as being unpatentable over Chang (U.S. Pat. No. 6,129,916) in view of the well-known and art-recognize use of avidin-biotin complexes to couple antibodies to solid phase surfaces, including tissue culture dishes, as evidenced by Shattil (U.S. Pat. No. 5,561,047), each for the reasons of record in Paper Nos. 19 and 26